Clinical trial

SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.

NCT05351788

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention SKB264 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention KL-A167 Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Carboplatin Normalized identity: carboplatinView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Cisplatin Normalized identity: cisplatinView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2022-05-20

PhasePHASE2

Conditions

Non-small Cell Lung Cancerverified · MONDO: non-small cell lung carcinoma

Interventions

SKB264DRUG

KL-A167DRUG

CarboplatinDRUG · verified · RxNorm: carboplatin

CisplatinDRUG · verified · RxNorm: cisplatin

Sponsors & collaborators

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.lead sponsor

Mapped research locations

GuangzhouGuangdong, China1 GuangzhouChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05351788 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.